Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 773-777

  Martínez Calatrava, María J ^a   González Sánchez, José L ^a   Zabena, Carina ^a   Martínez Larrad, María T ^a   Luque Otero, Manuel ^a   Serrano Ríos, Manuel ^a,b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b NONE   (Spain)

Author keywords

Gene polymorphism; Hypertension; Plasminogen activator inhibitor

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEALTH SURVEY; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLISM; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SMOKING; SPAIN; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 33947133749     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32803cae09     Document Type: Article

References (21)

1. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of reunin-angiotensin inhibition. Kidney Int 1997; 51:164-172.
2. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383:441-443.
3. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5:1135-1142.
4. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 10:264-269.
5. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104:839-844.
6. Lopes C, Dina C, Durand E, Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 2003; 46:1284-1290.
7. Sartori MT, Vettor R, De Pergols G, De Mitrio V, Saggiorato G, Della Mea P, et al. Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients. Influence of fat distribution and insulin-resistance. Thromb Haemost 2001; 86:1161-169.
8. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Di Bitondo R, Donati MB, Iacoviello L. 4G/5G promoter PAI-1 gene polymorphism is associatted with plasmatic activity in italians: a model of gene-environmet interaction. Thromb Haemost 1998; 79:354-358.
9. Martínez-Calatrava MJ, Martínez-Larrad MT, Zabena C, González-Sánchez JL, Fernández-Pérez C, Serrano-Ríos M. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obesity Metab 2007; 9:134-135.
10. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-10745.
11. Grenett HE, Benza RL, Fless GM, Li XN, Davis GC, Booyse FM. Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:1803-1809.
12. Martínez-Larrad MT, Fernández-Pérez C, González-Sánchez JL, López A, Fernández- Álvarez J, Riviriego J, Serrano-Ríos M, Grupo de Estudio de Atención Primaria de Segovia. Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia. Med Clin (Barc) 2005; 125:481-486.
13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
14. The Expert Comittee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
16. Hoekstra T, Geleijnse JM, Waart F, Nederhand R, Kluft C, Kok FJ, Schouten EG. The 4G/5G polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers. Thromb Res 2002; 107:115-119.
17. Roncal C, Orbe J, Rodriguez JA, Belzunce M, Beloqui O, Diez J, Páramo JA. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endotelial cells and in patients with hipertensión. Cardiovasc Res 2004; 63:176-185.
18. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vesshione G, Grandone E, Pennelli O. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:152-56.
19. Guan LX, Du XY, Wang JX, Wang RL, Wu ZL, Jiang H. Relationship between the 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and the pathogenesis of pregancy-induced hypertension syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004; 21:173-75.
20. Grilo A, Fernandez ML, Beltran M, Ramirez-Lorca R, Gonzalez MA, Royo JL, et al. Genetic analysis of CAV1 gene in hypertension and metabolic syndrome. Thromb Haemost 2006; 95:696-701.
21. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 1998; 32:459-466.